2006
DOI: 10.1016/j.gie.2005.09.028
|View full text |Cite
|
Sign up to set email alerts
|

A randomized comparison of EUS-guided FNA versus CT or US-guided FNA for the evaluation of pancreatic mass lesions

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

3
102
1
4

Year Published

2008
2008
2021
2021

Publication Types

Select...
5
3
2

Relationship

0
10

Authors

Journals

citations
Cited by 186 publications
(110 citation statements)
references
References 40 publications
3
102
1
4
Order By: Relevance
“…135 A recent prospective randomized study comparing CT or ultrasound-guided FNA with EUS-FNA showed that EUS-FNA is the preferred modality, especially for tumors smaller than 3 cm that have not been identified by previous ultrasound or CT examinations. 136 The main advantage of EUS-FNA is the possibility to target, small, intrapancreatic masses not visualized on CT. 53,124 EUS can also target small tumors such as neuroendocrine tumors and metastatic lesions to the pancreas, which are difficult to access via percutaneous guidance. 137 The indications of EUS-FNA for pancreatic cancer lesions are more controversial, but they currently include 50 : patients with distant metastasis and advanced locoregional disease before the initiation of chemoradiotherapy; diagnosis in resectable patients to exclude other rare pathology (lymphoma, small cell carcinoma, metastasis, etc) or to alter the planned surgery to perform organ-preserving surgery (neuroendocrine tumors, papillary cancers, etc); patient preference and desire to know the complete diagnosis before any planned invasive surgical treatment.…”
Section: Eus-fnamentioning
confidence: 99%
“…135 A recent prospective randomized study comparing CT or ultrasound-guided FNA with EUS-FNA showed that EUS-FNA is the preferred modality, especially for tumors smaller than 3 cm that have not been identified by previous ultrasound or CT examinations. 136 The main advantage of EUS-FNA is the possibility to target, small, intrapancreatic masses not visualized on CT. 53,124 EUS can also target small tumors such as neuroendocrine tumors and metastatic lesions to the pancreas, which are difficult to access via percutaneous guidance. 137 The indications of EUS-FNA for pancreatic cancer lesions are more controversial, but they currently include 50 : patients with distant metastasis and advanced locoregional disease before the initiation of chemoradiotherapy; diagnosis in resectable patients to exclude other rare pathology (lymphoma, small cell carcinoma, metastasis, etc) or to alter the planned surgery to perform organ-preserving surgery (neuroendocrine tumors, papillary cancers, etc); patient preference and desire to know the complete diagnosis before any planned invasive surgical treatment.…”
Section: Eus-fnamentioning
confidence: 99%
“…Currently, the procedure with the highest sensitivity for cancer is cytologic evaluation of fine-needle aspirates taken during endoscopic ultrasound (Figure 3f). In one randomized study in patients with suspected pancreatic cancer, rates for the detection of cancer in fineneedle aspirates were higher for specimens taken by endoscopic ultrasound (84%) than for specimens taken percutaneously under ultrasound or CT control (62%) (Horwhat et al, 2006). Similar results have been obtained for confirmation of bile duct cancer although the yield was significantly higher in distal cancer (81%) than in proximal cancer (59%) (Mohamadnejad et al, 2011).…”
Section: Tissue Samplingmentioning
confidence: 64%
“…� ��ndomized com���ison be��een ���-��� �nd CT-o� ��-guided ��� �o� m��ign�n� ��nc�e��ic �umo�s ��so �eve��ed sensi�ivi�ies o� ��4% �nd 62%, �es�ec�ive�y. T�us, ���-��� ��s su�e�io� �o CT-, ���-��� ��s su�e�io� �o CT-���-��� ��s su�e�io� �o CT-� o� ��-guided ���, es�eci���y �o� sm��� m�sses di�ficu�� �o de�ec� �i�� CT o� �� [23] 23] ] �� �sing ��� o� sc���nnom�s, i� is di�ficu�� �o find � s��e i� is di�ficu�� �o find � s��e i� is di�ficu�� �o find � s��e di�ficu�� �o find � s��e a sa�e sa�e �ou�e ��om ��e skin �o ��e �esion, es�eci���y in medi�s�in��, ��e skin �o ��e �esion, es�eci���y in medi�s�in��, skin �o ��e �esion, es�eci���y in medi�s�in��, the ��esion�� es�ecia����� in me��iastina���� ��esion�� es�ecia����� in me��iastina���� �� es�ecia����� in me��iastina���� es�ecia����� in me��iastina���� �erirecta�� or retro�eritonea�� masses [21] …”
Section: Discussionmentioning
confidence: 99%